Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults aged 18 years and older. Duloxetine is not approved for use in pediatric patients.
Chronic pain negatively impacts a person's quality of life. Often, over the counter pain medication, such as ibuprofen or aspirin, are ineffective in alleviating chronic pain. In these instances, a surprising choice is often a drug used to treat an entirely different condition - depression.
A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain.
A study led by Ravi Bansal, PhD, and Bradley S. Peterson, MD, of The Saban Research Institute of Children's Hospital Los Angeles, has found structural differences in the cerebral cortex of patients with depression and that these differences normalize with appropriate medication.
An estimated 60 to 70 percent of people with diabetes develop some form of diabetic neuropathy, or the chronic nerve damage diabetes causes, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
A functional MRI brain scan may help predict which patients will respond positively to antidepressant therapy, according to a new study published in the journal Brain.
A drug typically used to treat depression and anxiety can significantly reduce joint pain in postmenopausal women being treated for early stage breast cancer, according to new SWOG research to be presented Friday at a special plenary presentation at the San Antonio Breast Cancer Symposium.
Queen's University researcher Ian Gilron has uncovered a more effective way of treating fibromyalgia, a medical condition characterized by chronic widespread pain typically accompanied by fatigue, as well as sleep, mood and memory problems.
The majority of antidepressants prescribed to treat children and teenagers with major depression are ineffective and may even be unsafe, warn researchers.
An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression.
Botulinum toxin A injections have a sustained beneficial effect in patients with neuropathic pain, shows a randomised trial.
A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients.
AVACEN Medical announced today that it has launched a $2 million campaign on Crowdfunder.com to support further company clinical trials and FDA applications.
Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Duloxetine Delayed-release Capsules.
Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).
BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.
Patients with fibromyalgia syndrome (FMS) typically have widespread chronic pain and fatigue. For those with low vitamin D levels, vitamin D supplements can reduce pain and may be a cost-effective alternative or adjunct to other treatment, say researchers in the January 2014 issue of PAIN-.
The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results.
Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.
Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.
The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain.